Tag Archives: AstraZeneca

A Few Words About Diversification

By Julian Upton | Published: February 1, 2010

Guest blog by Dr Brian White, an analyst at Shore Capital. As a result of the feared impact of the patent expiry cliff, the decimation of branded sales by multi-sourced generics and the obstacles erected, especially by managed care in the US, to slow the uptake of branded pharmaceuticals where a generic in the same class [...]

Posted in Europe, Global, Guest Blog, Strategy | Also tagged diagnostics, diversification, GSK, Merck & Co, Novartis, Schering Plough | Leave a comment

AstraZeneca to Slash 8,000 More Jobs (Updated 2/3/10)

By Oriana Schwindt | Published: January 28, 2010

Last year, AstraZeneca announced the elimination of some 15,000 jobs. Last Thursday, the London-based company revealed that it plans to lay off another 8,000 by 2014—this despite global revenue growth of 4 percent for 2009. Much of the drive for this addition labor sculpting stems from AZ’s desire to streamline its R&D; the company will focus [...]

Posted in Strategy | Also tagged business, Company, David Brennan, Employment, GlaxoSmithKline, layoffs, London, Research and development | 1 Comment

Novartis Names Jimenez CEO

By George Koroneos | Published: January 26, 2010

Novartis shocked investors on Tuesday morning when the Swiss-based firm announced that CEO Daniel Vasella would relinquish his post as CEO to Joe Jimenez while retaining his chairman of the board spot. According to a release, this move has been in the works since 2008 and lead to the restructuring of its management team. The executive [...]

Posted in Strategy | Also tagged business, Chief financial officer, Daniel Vasella, Novartis, Switzerland | 2 Comments

AZ’s First Corporate Blog Falls Flat

By Andrew Sheivachman | Published: November 4, 2009

Currently, if patients or doctors look for specific drug information on AZ Health Connections, AstraZeneca’s new corporate communications blog, they won’t find any. And that’s exactly how AZ—along with pretty much every other pharma company engaged in the social media sphere—wants it. “The one area we’re trying not to engage is specific questions about disease state,” [...]

Posted in E-Media | Also tagged Community, Company, Food and Drug Administration, Health care, social media, Virtual community, Washington DC | 3 Comments

AstraZeneca, BMS Announce Layoffs and Buyouts

By George Koroneos | Published: October 21, 2009

AstraZeneca was the topic of conversation this week as word broke that the company is offering buyout deals to every member of its 5,500 US sales force. “AstraZeneca is making changes to our sales force, which will be managed first by looking at vacancies and offering field sales employees the opportunity to self-identify whether they are [...]

Posted in Strategy | Also tagged Bristol Myers Squibb, Buyouts, Indiana, layoffs, New York City, Pfizer, Strategy, Wyeth | 1 Comment